Mathilde Bourdon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mathilde Bourdon has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Pietro Santulli
Faculté de Santé, Université Paris Cité, Paris, France
23 shared publications - Charles Chapron
Faculté de Santé, Université Paris Cité, Paris, France
12 shared publications Chloé Maignien
12 shared publications- Louis Marcellin
Université Paris-Cité, Paris, France
10 shared publications Charles Chapron
9 shared publications- Catherine Patrat
INSERM 1016
8 shared publications
Latest Publications
- 3 November 2026
- Published by Elsevier in The Lancet Obstetrics, Gynaecology, & Women's Health
- Vol. 2 (11) , e1022-e1034
Adenomyosis and infertility: an under-recognised challenge
- 3 November 2026
- Published by Elsevier in The Lancet Obstetrics, Gynaecology, & Women's Health
- Vol. 2 (11) , e1022-e1034
Adenomyosis and infertility: an under-recognised challenge
- Open Access
- 2 November 2026
- Published by Elsevier in Reproductive BioMedicine Online
Impact of endometriosis on cumulative live birth rates after donor sperm intrauterine insemination
- 2 November 2026
- Published by Elsevier in Reproductive BioMedicine Online
Open AccessImpact of endometriosis on cumulative live birth rates after donor sperm intrauterine insemination
- Open Access
- 17 September 2026
- Published by Elsevier in F&S Reports
Preserving fertility before hematopoietic stem cell transplantation in women with sickle cell anemia
- 17 September 2026
- Published by Elsevier in F&S Reports
Open AccessPreserving fertility before hematopoietic stem cell transplantation in women with sickle cell anemia
- Open Access
- 12 September 2026
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 55 (9)
Is in-vitro fertilization a risk factor for perinatal morbidity in late term pregnancies beyond 41 weeks of gestation? A comparative retrospective study
- 12 September 2026
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 55 (9)
Open AccessIs in-vitro fertilization a risk factor for perinatal morbidity in late term pregnancies beyond 41 weeks of gestation? A comparative retrospective study
- 22 July 2026
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 32 (6) , 717-734
Clinical outcomes of Day-7 blastocysts: a systematic review and meta-analysis
BACKGROUND: Extended embryo culture beyond Day-6 remains controversial. While a small subset of embryos reaches the blastocyst stage on Day-7, their developmental competence and reproductive potential remain uncertain. Data from previous studies have been limited and heterogeneous, particularly for meta-analytical evaluation of euploid embryo transfers. OBJECTIVE AND RATIONALE: This systematic review and meta-analysis compared clinical pregnancy (CPR) and live birth rates (LBR), as well as implantation (IR), miscarriage (MR), and ongoing pregnancy rates (OPR), between Day-7 frozen blastocysts and those obtained on Day-5 and/or Day-6. Euploidy rates by day of blastocyst development and available perinatal outcomes were also assessed. SEARCH METHODS: Conducted according to PRISMA guidelines, this review included full-length English-language human studies, published up to 1 April 2026, comparing frozen transfers of Day-7 versus Day-5/6 blastocysts and reporting at least clinical pregnancy and/or live birth outcomes. Random-effects models were used to estimate pooled odds ratios (ORs) with 95% confidence intervals (95% CI). Obstetric and perinatal outcomes were analysed when available. OUTCOMES: A total of 17 retrospective studies were included. Across 2908 Day-7 transfers, CPR and LBR were significantly lower than for Day-5 (CPR: OR 0.26, 95% CI 0.19–0.35, I2: 76.2%, 16 studies, 2799 and 34 442 transfers at Day-7 and Day-5, respectively; LBR: OR 0.23, 95% CI 0.16–0.33, I2: 76.3%, 12 studies, 2687 and 31 630 transfers at Day-7 and Day-5, respectively) and Day-6 blastocysts (CPR: OR 0.38, 95% CI 0.31–0.48, I2: 54.4%, 16 studies, 2799 and 28 563 transfers at Day-7 and Day-6, respectively; LBR: OR 0.37, 95% CI 0.28–0.49, I2: 60.2%, 12 studies, 2687 and 26 687 transfers at Day-7 and Day-6, respectively). Similarly, IR and OPR were significantly lower in the Day-7 group than in the Day-5 or Day-6 groups, while MR was higher compared with Day-5 blastocysts (OR 1.54, 95% CI 1.04–2.30, I2: 51.1%, 14 studies, 685 and 18 609 pregnancies at Day-7 and Day-5, respectively). When considering only PGT-A euploid blastocysts, CPR and LBR remained significantly lower in the Day-7 group compared with Day-5 (CPR: OR 0.21, 95% CI 0.14–0.33, I2: 58.0%, 7 studies, 365 and 7064 transfers at Day-7 and Day-5, respectively; LBR: OR 0.21, 95% CI 0.17–0.28, I2: 0%, 6 studies, 364 and 5924 transfers at Day-7 and Day-5, respectively) and Day-6 (CPR: OR 0.36, 95% CI 0.28–0.46, I2: 40.8%, 7 studies, 365 and 4617 transfers at Day-7 and Day-6, respectively; LBR: OR 0.36, 95% CI 0.28–0.46, I2: 0%, 6 studies, 364 and 3782 transfers at Day-7 and Day-6, respectively), and MR was higher than Day-5 (OR 2.78, 95% CI 1.57–4.89, I2: 32.4%, 6 studies, 95 and 4018 pregnancies at Day-7 and Day-5, respectively). Euploid rates were also significantly reduced for Day-7 blastocysts compared with Day-5 and Day-6. Data on perinatal outcomes were limited but overall reassuring. The pooled analyses revealed low to high heterogeneity across studies. WIDER IMPLICATIONS: Despite lower success rates, including for euploid embryos, Day-7 blastocysts may still contribute to cumulative live birth rates, notably in poor-prognosis patients. Prospective studies are needed to better assess perinatal and long-term outcomes. REGISTRATION NUMBER: PROSPERO (CRD420251114251)
- 22 July 2026
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 32 (6) , 717-734
Clinical outcomes of Day-7 blastocysts: a systematic review and meta-analysis
BACKGROUND: Extended embryo culture beyond Day-6 remains controversial. While a small subset of embryos reaches the blastocyst stage on Day-7, their developmental competence and reproductive potential remain uncertain. Data from previous studies have been limited and heterogeneous, particularly for meta-analytical evaluation of euploid embryo transfers. OBJECTIVE AND RATIONALE: This systematic review and meta-analysis compared clinical pregnancy (CPR) and live birth rates (LBR), as well as implantation (IR), miscarriage (MR), and ongoing pregnancy rates (OPR), between Day-7 frozen blastocysts and those obtained on Day-5 and/or Day-6. Euploidy rates by day of blastocyst development and available perinatal outcomes were also assessed. SEARCH METHODS: Conducted according to PRISMA guidelines, this review included full-length English-language human studies, published up to 1 April 2026, comparing frozen transfers of Day-7 versus Day-5/6 blastocysts and reporting at least clinical pregnancy and/or live birth outcomes. Random-effects models were used to estimate pooled odds ratios (ORs) with 95% confidence intervals (95% CI). Obstetric and perinatal outcomes were analysed when available. OUTCOMES: A total of 17 retrospective studies were included. Across 2908 Day-7 transfers, CPR and LBR were significantly lower than for Day-5 (CPR: OR 0.26, 95% CI 0.19–0.35, I2: 76.2%, 16 studies, 2799 and 34 442 transfers at Day-7 and Day-5, respectively; LBR: OR 0.23, 95% CI 0.16–0.33, I2: 76.3%, 12 studies, 2687 and 31 630 transfers at Day-7 and Day-5, respectively) and Day-6 blastocysts (CPR: OR 0.38, 95% CI 0.31–0.48, I2: 54.4%, 16 studies, 2799 and 28 563 transfers at Day-7 and Day-6, respectively; LBR: OR 0.37, 95% CI 0.28–0.49, I2: 60.2%, 12 studies, 2687 and 26 687 transfers at Day-7 and Day-6, respectively). Similarly, IR and OPR were significantly lower in the Day-7 group than in the Day-5 or Day-6 groups, while MR was higher compared with Day-5 blastocysts (OR 1.54, 95% CI 1.04–2.30, I2: 51.1%, 14 studies, 685 and 18 609 pregnancies at Day-7 and Day-5, respectively). When considering only PGT-A euploid blastocysts, CPR and LBR remained significantly lower in the Day-7 group compared with Day-5 (CPR: OR 0.21, 95% CI 0.14–0.33, I2: 58.0%, 7 studies, 365 and 7064 transfers at Day-7 and Day-5, respectively; LBR: OR 0.21, 95% CI 0.17–0.28, I2: 0%, 6 studies, 364 and 5924 transfers at Day-7 and Day-5, respectively) and Day-6 (CPR: OR 0.36, 95% CI 0.28–0.46, I2: 40.8%, 7 studies, 365 and 4617 transfers at Day-7 and Day-6, respectively; LBR: OR 0.36, 95% CI 0.28–0.46, I2: 0%, 6 studies, 364 and 3782 transfers at Day-7 and Day-6, respectively), and MR was higher than Day-5 (OR 2.78, 95% CI 1.57–4.89, I2: 32.4%, 6 studies, 95 and 4018 pregnancies at Day-7 and Day-5, respectively). Euploid rates were also significantly reduced for Day-7 blastocysts compared with Day-5 and Day-6. Data on perinatal outcomes were limited but overall reassuring. The pooled analyses revealed low to high heterogeneity across studies. WIDER IMPLICATIONS: Despite lower success rates, including for euploid embryos, Day-7 blastocysts may still contribute to cumulative live birth rates, notably in poor-prognosis patients. Prospective studies are needed to better assess perinatal and long-term outcomes. REGISTRATION NUMBER: PROSPERO (CRD420251114251)
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Adénomyose : implication du système immunitaire
L'adénomyose est une pathologie chronique bénigne de l'utérus caractérisée par la présence de glandes endométriales et de stroma au sein du myomètre. C'est une maladie hétérogène, présentant des formes cliniques distinctes selon la localisation des lésions dans le myomètre. Cette maladie fréquente peut être responsable de symptômes invalidants comme des dysménorrhées, des saignements utérins anormaux et/ou une infertilité. Sa pathogenèse est très peu comprise aujourd'hui et plusieurs théories ont été proposées. Certaines suggèrent que le développement de l'adénomyose est de novo, à partir de reliquats müllériens ou de cellules souches. Néanmoins, selon la théorie la plus communément admise, l'adénomyose trouverait son origine dans la couche basale de l'endomètre avec une invagination de cellules entre les faisceaux musculaires. De multiples facteurs pourraient être impliqués dans l'initiation de cette invasion, et notamment des modifications immunitaires. Afin d'explorer l'implication du système immunitaire dans la pathogenèse de l'adénomyose, nous avons réalisé une revue systématique de la littérature portant sur les modifications immunitaires décrites dans l'adénomyose chez l'Humain. Cette analyse a montré la présence de changements immunitaire tant innés qu'adaptatifs, au niveau local utérin ou systémique chez les femmes atteintes d'adénomyose par rapport aux contrôles. Ensuite, nous avons étudié la concentration sérique systémique de cytokines selon la présence d'une adénomyose. Nous avons montré une diminution des taux sériques de cytokines pro-inflammatoires et immunorégulatrices (IL17F, IL23, IL25, IL31 et IL33) chez les femmes atteintes d'adénomyose par rapport aux contrôles.Nous avons ensuite étudié dans le sérum, le profil métabolique de femmes avec adénomyose. Celles-ci avaient un profil métabolique différent par rapport à celui des contrôles. Les métabolites différentiellement retrouvés semblaient impliqués dans l'activation immunitaire ainsi que dans la prolifération et la migration cellulaire. De plus, nos résultats ont suggéré qu'un certain nombre de voies métaboliques étaient spécifiques selon le phénotype d'adénomyose. Enfin, nous avons reproduit un modèle d'adénomyose murin, précédemment décrite par l'équipe de Guo S-W. Nous avons cherché à étudier dans ce modèle, le rôle des cellules immunitaires et de la voie NOTCH1 dans le développement de l'adénomyose, notamment via l'activation d'une transition épithélio-mésenchymateuse (TEM), phénomène décrit dans l'invasion du myomètre par des cellules endométriales dans l'adénomyose. Nous avons montré une augmentation de certains marqueurs de cellules immunitaires, notamment les macrophages M1 et les cellules Natural Killer à 30 jours et une augmentation des marqueurs des cellules T CD4+ à 60 jours de vie, dans l'utérus de souris adénomyosiques par rapport aux contrôles. Parallèlement, la protéine NOTCH1 activé ainsi que certains marqueurs de la TEM étaient augmentés, suggérant que les modifications immunitaires et l'activation NOTCH1 dans l'utérus pourraient être en lien avec le développement des lésions d'adénomyose. En conclusion, nous avons confirmé la présence de modifications immunitaires dans la pathogenèse de l'adénomyose, tant au niveau systémique que local au niveau de l'utérus. Nous avons mis en évidence dans l'adénomyose, un déséquilibre de la balance des cytokines systémiques anti-inflammatoires/pro-inflammatoires ainsi qu'un profil métabolique différent par rapport aux contrôles. Nous avons également montré une expression aberrante de plusieurs marqueurs des cellules immunitaires au sein de l'utérus de souris adénomyosiques au cours du développement de la maladie ainsi qu'une activation de la voie NOTCH1 et des signaux de TEM. Ces résultats confirment que certains médiateurs immuns sont impliqués dans la pathogenèse de l'adénomyose et probablement dans le processus d'invasion cellulaire des cellules endométriales vers le myomètre.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Adénomyose : implication du système immunitaire
L'adénomyose est une pathologie chronique bénigne de l'utérus caractérisée par la présence de glandes endométriales et de stroma au sein du myomètre. C'est une maladie hétérogène, présentant des formes cliniques distinctes selon la localisation des lésions dans le myomètre. Cette maladie fréquente peut être responsable de symptômes invalidants comme des dysménorrhées, des saignements utérins anormaux et/ou une infertilité. Sa pathogenèse est très peu comprise aujourd'hui et plusieurs théories ont été proposées. Certaines suggèrent que le développement de l'adénomyose est de novo, à partir de reliquats müllériens ou de cellules souches. Néanmoins, selon la théorie la plus communément admise, l'adénomyose trouverait son origine dans la couche basale de l'endomètre avec une invagination de cellules entre les faisceaux musculaires. De multiples facteurs pourraient être impliqués dans l'initiation de cette invasion, et notamment des modifications immunitaires. Afin d'explorer l'implication du système immunitaire dans la pathogenèse de l'adénomyose, nous avons réalisé une revue systématique de la littérature portant sur les modifications immunitaires décrites dans l'adénomyose chez l'Humain. Cette analyse a montré la présence de changements immunitaire tant innés qu'adaptatifs, au niveau local utérin ou systémique chez les femmes atteintes d'adénomyose par rapport aux contrôles. Ensuite, nous avons étudié la concentration sérique systémique de cytokines selon la présence d'une adénomyose. Nous avons montré une diminution des taux sériques de cytokines pro-inflammatoires et immunorégulatrices (IL17F, IL23, IL25, IL31 et IL33) chez les femmes atteintes d'adénomyose par rapport aux contrôles.Nous avons ensuite étudié dans le sérum, le profil métabolique de femmes avec adénomyose. Celles-ci avaient un profil métabolique différent par rapport à celui des contrôles. Les métabolites différentiellement retrouvés semblaient impliqués dans l'activation immunitaire ainsi que dans la prolifération et la migration cellulaire. De plus, nos résultats ont suggéré qu'un certain nombre de voies métaboliques étaient spécifiques selon le phénotype d'adénomyose. Enfin, nous avons reproduit un modèle d'adénomyose murin, précédemment décrite par l'équipe de Guo S-W. Nous avons cherché à étudier dans ce modèle, le rôle des cellules immunitaires et de la voie NOTCH1 dans le développement de l'adénomyose, notamment via l'activation d'une transition épithélio-mésenchymateuse (TEM), phénomène décrit dans l'invasion du myomètre par des cellules endométriales dans l'adénomyose. Nous avons montré une augmentation de certains marqueurs de cellules immunitaires, notamment les macrophages M1 et les cellules Natural Killer à 30 jours et une augmentation des marqueurs des cellules T CD4+ à 60 jours de vie, dans l'utérus de souris adénomyosiques par rapport aux contrôles. Parallèlement, la protéine NOTCH1 activé ainsi que certains marqueurs de la TEM étaient augmentés, suggérant que les modifications immunitaires et l'activation NOTCH1 dans l'utérus pourraient être en lien avec le développement des lésions d'adénomyose. En conclusion, nous avons confirmé la présence de modifications immunitaires dans la pathogenèse de l'adénomyose, tant au niveau systémique que local au niveau de l'utérus. Nous avons mis en évidence dans l'adénomyose, un déséquilibre de la balance des cytokines systémiques anti-inflammatoires/pro-inflammatoires ainsi qu'un profil métabolique différent par rapport aux contrôles. Nous avons également montré une expression aberrante de plusieurs marqueurs des cellules immunitaires au sein de l'utérus de souris adénomyosiques au cours du développement de la maladie ainsi qu'une activation de la voie NOTCH1 et des signaux de TEM. Ces résultats confirment que certains médiateurs immuns sont impliqués dans la pathogenèse de l'adénomyose et probablement dans le processus d'invasion cellulaire des cellules endométriales vers le myomètre.
- 26 December 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (3) , 443-452
Obstetrical, perinatal, and children’s health outcomes following fresh embryo transfer after extended embryo culture
STUDY QUESTION: Does extended embryo culture (EEC) associate with an increased risk of obstetrical, perinatal, or children’s health complications? SUMMARY ANSWER: After thorough adjustment, EEC was not associated with widespread increased risks, although a moderate excess risk persisted for a few specific outcomes, notably cardiac anomalies, whereas reduced risks were observed for gestational diabetes, small birthweight, and musculoskeletal-limb anomalies. WHAT IS KNOWN ALREADY: EEC is increasingly used in IVF cycles. While blastocyst transfer (day-5/6) often improves birth rates, concerns remain about its impact on maternal and child health. STUDY DESIGN, SIZE, DURATION: In this nationwide longitudinal cohort study, all live-born singletons conceived through IVF—with or without sperm microinjection—and following fresh embryo transfer between 2014 and 2019 in France were included and followed for up to 8 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were obtained from the French National Health System and the National Biomedicine Agency registries. A comparative study was conducted between singletons conceived at either day-2/3 (cleavage-stage embryos group) or day-5/6 (EEC group). Data from both registries were cross-linked to identify obstetrical, perinatal, and health outcomes, including major congenital malformations, hospitalizations, and surgical interventions. Multivariable logistic and survival models were used to adjust for maternal, paternal, and treatment-related factors. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 41 315 singletons were included (25 816 and 15 499 from day-2/3 and day-5/6 groups, respectively). Most outcomes were similar between groups, notably the incidence of global major congenital malformations. However, EEC was associated with increased risks of placenta praevia (aOR, 1.16; 95% CI, 1.02–1.30), admission in neonatal intensive care unit (aOR, 1.16; 95% CI, 1.05–1.29), and cardiac anomalies at age 3 years (aHR, 1.78; 95% CI, 1.21–2.60). Conversely, the risk of gestational diabetes (aOR, 0.94; 95% CI, 0.88–1.00; P = 0.041) and small birthweight (aOR, 0.94; 95% CI, 0.88–1.00, P = 0.039) was lower, as was the risk of musculoskeletal-limb anomalies (aHR, 0.63; 95% CI, 0.42–0.97)—a finding that persisted up to age 7. Other health outcomes were largely comparable. LIMITATIONS, REASONS FOR CAUTION: One limitation of this study is that the data refer to live-born singletons, with stillbirths and medical terminations excluded from the analyses. Despite extensive adjustments, residual confounding cannot be excluded. Findings for specific pathologies/malformations should be interpreted with caution because the number of cases was small in some sub-groups. WIDER IMPLICATIONS OF THE FINDINGS: In this large and unique study, after adjusting for multiple maternal, paternal, and cycle-related variables, our findings provide some reassurance regarding the safety of prolonged in vitro embryo culture. A moderate risk remained for a few maternal and child health conditions following EEC—warranting further investigation—whereas the risk was notably lower compared to short embryo culture, particularly for musculoskeletal-limb anomalies. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the AOI of University Hospital of Dijon. The authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.
- 26 December 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (3) , 443-452
Obstetrical, perinatal, and children’s health outcomes following fresh embryo transfer after extended embryo culture
STUDY QUESTION: Does extended embryo culture (EEC) associate with an increased risk of obstetrical, perinatal, or children’s health complications? SUMMARY ANSWER: After thorough adjustment, EEC was not associated with widespread increased risks, although a moderate excess risk persisted for a few specific outcomes, notably cardiac anomalies, whereas reduced risks were observed for gestational diabetes, small birthweight, and musculoskeletal-limb anomalies. WHAT IS KNOWN ALREADY: EEC is increasingly used in IVF cycles. While blastocyst transfer (day-5/6) often improves birth rates, concerns remain about its impact on maternal and child health. STUDY DESIGN, SIZE, DURATION: In this nationwide longitudinal cohort study, all live-born singletons conceived through IVF—with or without sperm microinjection—and following fresh embryo transfer between 2014 and 2019 in France were included and followed for up to 8 years. PARTICIPANTS/MATERIALS, SETTING, METHODS: Data were obtained from the French National Health System and the National Biomedicine Agency registries. A comparative study was conducted between singletons conceived at either day-2/3 (cleavage-stage embryos group) or day-5/6 (EEC group). Data from both registries were cross-linked to identify obstetrical, perinatal, and health outcomes, including major congenital malformations, hospitalizations, and surgical interventions. Multivariable logistic and survival models were used to adjust for maternal, paternal, and treatment-related factors. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 41 315 singletons were included (25 816 and 15 499 from day-2/3 and day-5/6 groups, respectively). Most outcomes were similar between groups, notably the incidence of global major congenital malformations. However, EEC was associated with increased risks of placenta praevia (aOR, 1.16; 95% CI, 1.02–1.30), admission in neonatal intensive care unit (aOR, 1.16; 95% CI, 1.05–1.29), and cardiac anomalies at age 3 years (aHR, 1.78; 95% CI, 1.21–2.60). Conversely, the risk of gestational diabetes (aOR, 0.94; 95% CI, 0.88–1.00; P = 0.041) and small birthweight (aOR, 0.94; 95% CI, 0.88–1.00, P = 0.039) was lower, as was the risk of musculoskeletal-limb anomalies (aHR, 0.63; 95% CI, 0.42–0.97)—a finding that persisted up to age 7. Other health outcomes were largely comparable. LIMITATIONS, REASONS FOR CAUTION: One limitation of this study is that the data refer to live-born singletons, with stillbirths and medical terminations excluded from the analyses. Despite extensive adjustments, residual confounding cannot be excluded. Findings for specific pathologies/malformations should be interpreted with caution because the number of cases was small in some sub-groups. WIDER IMPLICATIONS OF THE FINDINGS: In this large and unique study, after adjusting for multiple maternal, paternal, and cycle-related variables, our findings provide some reassurance regarding the safety of prolonged in vitro embryo culture. A moderate risk remained for a few maternal and child health conditions following EEC—warranting further investigation—whereas the risk was notably lower compared to short embryo culture, particularly for musculoskeletal-limb anomalies. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the AOI of University Hospital of Dijon. The authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
- 5 December 2025
- Published by Springer Nature in Microbiome
- Vol. 13 (1) , 251
Microbiota insights in endometriosis
Endometriosis affects approximately 10% of women of reproductive age and is characterized by the presence of endometrial-like tissue outside the uterine ca
- 5 December 2025
- Published by Springer Nature in Microbiome
- Vol. 13 (1) , 251
Open AccessMicrobiota insights in endometriosis
Endometriosis affects approximately 10% of women of reproductive age and is characterized by the presence of endometrial-like tissue outside the uterine ca
- Open Access
- 27 November 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (2) , 225-237
Risk of cardiovascular disease and mortality among women with endometriosis: A systematic review and meta‐analysis
Introduction: Endometriosis is a chronic and estrogen‐dependent disorder that affects about 10% of women of reproductive age worldwide. Endometriosis has been associated with chronic inflammation and an atherogenic lipid profile, two conditions that increase the risk of atherothrombotic cardiovascular diseases. Material and Methods: A literature search for relevant studies published from the earliest record to 31 March 2025 was conducted in MEDLINE and EMBASE databases. The following MESH terms were searched: “stroke,” “cerebrovascular disease,” “cardiovascular disease,” “coronary heart disease,” “ischemic heart disease,” “mortality,” and “endometriosis.” The results of each study were pooled, and an overall estimate of relative risk was obtained with a random‐effect model. Homogeneity between studies was analyzed using I 2 statistics. This review was not registered. Results: Ten studies were eligible for inclusion in this meta‐analysis. Five studies reported an increased risk of stroke with endometriosis, with a pooled risk of 1.18 (95% confidence intervals [95% CI] [1.13–1.22]). Four studies reported an increased risk of coronary heart disease with endometriosis, with a pooled risk of 1.36 (95% CI [1.32–1.40]). Four studies reported an increased risk of composite cardiovascular disease with endometriosis, with a pooled risk of 1.16 (95% CI [1.12–1.20]). Although the homogeneity is high in results, the confounding factors considered in the different studies vary. Thus, these results must be interpreted with caution. Conclusions: Endometriosis is associated with an increased risk of cardiovascular disease. Further research is required to confirm these findings. However, these results highlight the importance of considering primary cardiovascular prevention strategies for women with endometriosis.
- 27 November 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (2) , 225-237
Open AccessRisk of cardiovascular disease and mortality among women with endometriosis: A systematic review and meta‐analysis
Introduction: Endometriosis is a chronic and estrogen‐dependent disorder that affects about 10% of women of reproductive age worldwide. Endometriosis has been associated with chronic inflammation and an atherogenic lipid profile, two conditions that increase the risk of atherothrombotic cardiovascular diseases. Material and Methods: A literature search for relevant studies published from the earliest record to 31 March 2025 was conducted in MEDLINE and EMBASE databases. The following MESH terms were searched: “stroke,” “cerebrovascular disease,” “cardiovascular disease,” “coronary heart disease,” “ischemic heart disease,” “mortality,” and “endometriosis.” The results of each study were pooled, and an overall estimate of relative risk was obtained with a random‐effect model. Homogeneity between studies was analyzed using I 2 statistics. This review was not registered. Results: Ten studies were eligible for inclusion in this meta‐analysis. Five studies reported an increased risk of stroke with endometriosis, with a pooled risk of 1.18 (95% confidence intervals [95% CI] [1.13–1.22]). Four studies reported an increased risk of coronary heart disease with endometriosis, with a pooled risk of 1.36 (95% CI [1.32–1.40]). Four studies reported an increased risk of composite cardiovascular disease with endometriosis, with a pooled risk of 1.16 (95% CI [1.12–1.20]). Although the homogeneity is high in results, the confounding factors considered in the different studies vary. Thus, these results must be interpreted with caution. Conclusions: Endometriosis is associated with an increased risk of cardiovascular disease. Further research is required to confirm these findings. However, these results highlight the importance of considering primary cardiovascular prevention strategies for women with endometriosis.